Exabis Library
Welcome to the e-CCO Library!
DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTE
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP45: Utilization and sustainability of biologics in CD - A nationwide study from the epi-IIRN
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP46 Impact of a genetic burden on familial aggregation of inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP46: Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP46: Extended induction treatment with mirikizumab in patients with moderately-to-severely active ulcerative colitis: results from a phase 2 trial
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP46: Metabolic adaptation to ER stress licences STING signalling in intestinal epithelial cells
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP46: Sustainability rate of immunomodulators monotherapy in patients with Crohn's Diseases: A population-based analysis from the epi-IIRN cohort
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP46: Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH study
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP47 The changing pattern of inflammatory bowel disease incidence in Northern France: A continuing increase in the young women (1988–2014)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP47: Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatment
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP47: Identification and characterization of T-cell receptor sequences associated with Crohn’s Disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP47: Real World Evidence on the effectiveness of ustekinumab in Crohn’s Disease: Induction phase results from the prospective, observational RUN-CD Study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the phase 3 UNIFI maintenance study
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP47: The changing pattern of Inflammatory Bowel Disease incidence in Northern France: A continuing increase in the young women (1988-2014)
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP47: The changing pattern of Inflammatory Bowel Disease incidence in Northern France: A continuing increase in the young women (1988-2014)
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1